Skip to content
Screener

D&A at other companies

XER
Xeris Biopharma Holdings, Inc.XERS
$323K-0.6%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$364K-78.0%
Upstream Bio, Inc. logo
Upstream Bio, Inc.UPB
$50K+19.0%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$19.64M-15.6%
TRV
Trevi Therapeutics, Inc.TRVI
$34K-8.1%
United Therapeutics logo
United TherapeuticsUTHR
$24.2M+14.7%

Other financials

Income statement

See full
Revenue-
Operating income-$41.0M-30.3%
Net income-$40.2M-32.3%
EPS (diluted)-$0.16-14.3%

Balance sheet

See full
Cash & equivalents$41.8M+140%
Total debt$31.2M+5.2%
Total equity$143.7M+19.2%
Total assets$192.1M+17.3%

Cash flow

See full
Operating cash flow-$29.7M-13.3%
CapEx$222.0K+1,380%
Free cash flow-$30.0M-14.1%

Valuation

See full
Market cap$1.17B+152%
Enterprise value$1.16B+143%

Profitability

See full
Operating margin-19,183.3%
Net margin-19,305.1%
FCF margin-15,518.7%

Returns & leverage

See full
Return on equity-105.5%+7.0pp
Debt / equity0.2×0.0×
Current ratio10.1×-0.9×

Where this comes from

Reported directly by Savara in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The source filing: Savara’s 10-Q, filed August 11, 2026. Open the filing →

Filed
Aug 11, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-344585

FAQ

What is Savara's D&A?
Savara (SVRA) reported D&A of $28K in Q2 2026.
How has Savara's D&A changed year-over-year?
Savara's D&A decreased by 17.6% year-over-year, from $34K to $28K.
What is the long-term trend for Savara's D&A?
Over 3 years (2021 to 2024), Savara's D&A has grown at a -1.5% compound annual growth rate (CAGR), from $136K to $130K.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Ask your AI about Savara's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude